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The Laboratory Capacity Team (LCT) in the Laboratory Branch 
(LB) of the Division of Tuberculosis Elimination (DTBE) at 
the U.S. Centers for Disease Control and Prevention (CDC) 
is pleased to present the “Fourth Edition of the Tuberculosis 
Laboratory Aggregate Report.” This report includes a 
comparison of aggregate workload data for calendar years 
2012, 2013, 2014, and 2015, and six-year trends (2010–2015) 
for turnaround time (TAT). Current public health laboratory 
(PHL) testing methods and practices for tuberculosis (TB) 
are also included in this report. Data are self-reported by PHL 
supported, in part, by the CDC TB Elimination Cooperative 
Agreement. Data serve as a tool to assess benchmarks and 
provide peer comparisons. Providing self-reported data back to 
grantees in a meaningful format is an important mission of LCT.
How to Get the Most from this Report
A key aspect of a quality assurance program is to monitor 
workload and TAT indicators within a laboratory. By assessing 
these indicators internally over time, as well as externally against 
peer data, laboratories can track progress and set realistic goals. 
The Fourth Edition of the Tuberculosis Laboratory Aggregate 
Report provides peer data for comparison and serves as a guide 
to define a laboratory’s TAT goals using national averages and 
trends. For example, if your laboratory is above the national 
average, continue those efforts. However, if your laboratory is 
below the national average, focus on efforts for improvement. 
The Aggregate Report also contains data that is stratified by 
laboratory volume for a more specific comparison among 
laboratories. Testing volume and courier service availability are 
stratified for direct comparison with similar laboratories. 
Use the data in this Aggregate Report to your advantage. 
Information from this report can be used to either document 
your program’s accomplishments or provide evidence 
to substantiate change within your laboratory, such as 
methodologies, protocols, or staffing.  
Please contact your LCT consultant with any questions 
regarding data requirements for the CDC TB Cooperative 
Agreement or your laboratory’s specific data. In addition, any 






CDC: United States Centers for Disease Control and Prevention
DST: Drug susceptibility testing
DTBE: Division of Tuberculosis Elimination
Hain LPA: Hain Lifescience. Commercial line probe assays that identify MTBC and can detect mutations 
associated with both rifampicin and isoniazid resistance.
HP 2020: Healthy People 2020 
HPLC: High Performance Liquid Chromatography
ID: Identification
IGRA: Interferon-Gamma Release Assay
INNO-LiPA®: Fujirebio. Commercial line probe assays that identify MTBC and can detect mutations 
associated with rifampin resistance.
LB: Laboratory Branch
LCT: Laboratory Capacity Team
MALDI-TOF: Matrix-assisted Laser Desorption Ionization Time of Flight. A mass-spectrometry-based assay 
for bacterial identification. 
BacTec MGIT™: Mycobacterium Growth Indicator Tube, Becton Dickinson and Co. A commercial 
non-radiometric broth-based mycobacterial culture system.
MTBC: Mycobacterium tuberculosis complex
MTD™: Mycobacterium Direct Test, Gen Probe, Inc. A commercial molecular assay for direct detection of 
MTBC in clinical specimens.
NAAT: Nucleic acid amplification test. Generic terminology for molecular method used for direct detection of 
MTBC in clinical specimens.
PCR: Polymerase chain reaction
PHL: Public health laboratory
PRA: PCR restriction analysis
Quantiferon®: Qiagen. A commercial blood test used to aid in diagnosis of TB infection. (IGRA)
Trek Sensititre: ThermoScientific. A commercial microtiter plate for minimum inhibitory concentration (MIC) 
testing of 12 antituberculosis drugs simultaneously.
TAT: Turnaround time
TB: Tuberculosis
T-SPOT®: Oxford ImmunoTec. A commercial blood test used to aid in diagnosis of TB infection. (IGRA)
Xpert™ MTB/RIF: Cepheid, Inc. A commercial molecular assay for direct detection of MTBC and mutations 
associated with rifampin resistance in clinical specimens.
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Technical Notes
1. Unless otherwise specified, the source of all data and information for the tables and figures in this report 
originates from Annual Performance Reports of the TB Elimination and Laboratory Cooperative Agreement 
submitted to CDC by US Public Health Laboratories that receive Cooperative Agreement funding. 
2. For Figure 3, public health laboratories were required to report data for each category for inclusion in 
the analysis.
3. For Figure 5, data for courier service were interpreted as accurately as possible from project narratives of 
Cooperative Agreement Annual Performance Reports.
4. For Figures 6–9, data for test methods were interpreted as accurately as possible from project narratives 
of Cooperative Agreement Annual Performance Reports.
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Laboratory Workload 
Changes in laboratory workload reported by PHL from 2012 through 2015 are listed by key variables in Table 1. While 
some variations in volume were noticed annually for this four year period, PHL reported a decrease in the number of 
clinical specimens received, patients for whom a specimen was submitted, patients culture positive for MTBC, patients 
for whom a reference isolate was submitted, and patients for whom a DST was performed. However, the number 
of patients tested by NAAT or other rapid test increased 39.5% while patients NAAT-positive for MTBC increased 
6.5%, providing evidence that PHL have increased use of molecular methods for detection of MTBC. In 2013, PHL 
began reporting use of IGRA for detection of TB infection as part of the Cooperative Agreement. A comparison of data 
collected in 2013 and 2015 showed a 6.5% increase in the number of IGRA tests performed in PHL.
Table 1. National Workload Data, 2012–2015.
Total No.
(Range among individual laboratories)
Four Year 
Change
No. (% change)2012 2013 2014 2015
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aProcessed and cultured, not including isolates referred from other laboratories, bProcessed and culture inoculated, cReceived to either rule 


















































































Diagnostic clinical specimens received, 2015
Figure 1. Distribution of PHL Testing Volumes Measured by Total Number of  
Clinical Specimens Received, 2015.
*These jurisdictions referred all TB testing to another laboratory. 
Note: D.C. = Washington, D.C., NYS = New York State, NYC = New York City, PR = Puerto Rico. All others are US Postal Service state abbreviations or cities.
The volume of public health diagnostic testing for TB is variable, as evidenced by widely distributed measurements of 
clinical specimens received. In 2015, 11 PHL received 1,000 or fewer specimens for AFB smear and culture, while 3 
PHL processed more than 15,000 specimens. Most PHL (n = 36) processed between 1,001 and 5,000 specimens. 
Some PHL process few clinical specimens, but may serve primarily as reference laboratories. These PHL may receive 
isolates and inoculated media from other laboratories within their jurisdictions. CDC and APHL recommend processing a 
minimum of 20 specimens per week1 (approximately 1,000 specimens per year) to maintain proficiency and recommend 
that laboratories with insufficient specimen volumes or those unable to provide accurate results in a timely manner 
consider sending specimens or cultures to qualified full service laboratories. Testing volume is only one potential 
indicator of proficiency. Many other factors contribute to the decision for a laboratory to continue mycobacteriology 


















































































Diagnostic clinical specimens received, 2015
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MTBC Culture Positivity 
Figure 2. Positivity of Cultures by Cooperative Agreement Site, 2015. 
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Percent patient specimens received that were culture positive for MTBC 
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The wide range of MTBC culture positivity (percent of individual patients’ specimens that were positive for MTBC 
in culture) observed among PHL is shown in Figure 2. This range may be indicative of differences in incidence 
of TB disease among patient populations served by PHL or may reflect the widely variable roles that PHL serve 
within their jurisdictions. For instance, in some areas, the state PHL may be the sole facility processing AFB 
specimens and therefore, may see a lower percent of cultures positive for MTBC; but in other areas, the PHL 
may function primarily in a reference laboratory capacity by receiving follow-up specimens after diagnosis and 
therefore, might encounter a relatively higher MTBC culture positivity. A number of other factors may influence 
MTBC culture positivity, including the nature of the patient population served by PHL, differences in clinicians’ 
practices in evaluating patients, or local incidence of nontuberculous mycobacteria (NTM) disease. The national 
culture positivity displayed is not indicative of a nationwide goal, but rather reflects the percent of all specimens 
received in PHL in 2015 that were positive for MTBC in culture, measured on a per-patient basis. It is important 
for individual laboratories to determine baseline MTBC culture positivity and monitor this percentage over time 
to detect fluctuations. While some variation might indicate change in disease incidence or patient population 
changes, significant incremental deviations in this indicator could also indicate potential laboratory issues such 
as false-positive cultures. Laboratories may wish to use the information in this graph to compare culture positivity 
among their peers in terms of similar testing volumes or geographic location.    
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Trends in Nucleic Acid Amplification Testing (NAAT)
























% patient specimens processed
that also had NAAT performed
% NAAT positivity % Culture (+)  TB confirmed 
in 48 hrs.*
2012 2013 2014 2015
n=56 n=57n=57 n=58 n=58 n=57 n=47 n=54 n=50 n=54n=55 n=57
Note: n = number of laboratories reporting data. % NAAT positivity = percent of nucleic acid amplification tests performed that were positive 
for MTBC. 
 
*Beginning in 2013, clarification was provided to indicate only those patients with culture-positive TB should be counted. In 2014,  
2 laboratories had 0 patients with culture-positive TB; these were excluded from analysis.  
The use of NAAT as part of a laboratory’s testing algorithm is essential for rapid detection of patients with TB. From 
2012 to 2015, while the percent of NAAT positivity decreased, expanded use of NAAT in PHL increased, as did 
improvement towards achievement of the HP 2020 goal of 77% of culture-confirmed TB detected by NAAT within 
48 hours. Since 2012, NAAT algorithms have evolved and consequently, the percent of patient specimens tested 
by NAAT has increased. PHL should consider examining local data to determine characteristics of MTBC culture 
positive patients, adjust their NAAT algorithm accordingly to detect more cases, and work with their TB Control 
Program to ensure testing of appropriate patients. Please see Technical Note #2 for explanation of how the number 
























% patient specimens processed
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% NAAT positivity % Culture (+)  TB confirmed 
in 48 hrs.*
2012 2013 2014 2015
n=56 n=57n=57 n=58 n=58 n=57 n=47 n=54 n=50 n=54n=55 n=57
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New DST TAT Benchmark
DST TAT is dependent on growth of MTBC in culture, as evidenced by the strong correlation between 
ID of MTBC and DST TATs (p < .05 for 2010 – 2013) reported in the Third Edition of the Aggregate 
Report3. To more accurately assess DST TAT measurement independent of growth of MTBC in culture 
prior to ID of MTBC, the benchmark was changed in 2014 to percent of DST results within 17 days of 
ID of MTBC, rather than the previous measurement of 28 days from specimen receipt. Specific national 
targets for each benchmark were set4. Analysis of 2014 TAT data supports this change, as no correlation 
between ID of MTBC and DST TAT was observed (correlation analysis, SPSS version 21). 
DST Reference Center
Beginning in 2015, DTBE in collaboration with APHL, established the National TB DST Reference 
Center at the California Microbial Diseases Laboratory. Among other services, the reference center 
performs first-line DST for those laboratories performing fewer than 50 DSTs per year. Currently, 10 
PHL use the Reference Center for first-line DST. Those laboratories are excluded from analysis of the 
DST TAT for 2015.
Turnaround Times
Table 2. Turnaround Time Indicators, 2015.
Benchmark
Specimen re-
ceipt within 1 
day of  
collection
AFB smear 
result within 1 
day of receipt
ID of MTBC 
within 21 days 
of receipt
DST within 
17 days of ID 
of MTBC
National Target 
(% of specimens that 
should meet benchmark)
67% 92% 74% 69%
No. laboratories meeting 
or exceeding National 
Target*
12 31 25 20†
National average* 
(% of specimens meeting 
benchmark)
48% 90% 69% 61%
No. laboratories  meet-
ing or exceeding  national 
average*
31 33 29 26†
*Number of laboratories reporting = 57. †10 PHL referring isolates to the DST Reference Center 
for first-line DST are excluded from analysis of the DST TAT for 2015.
10
Figure 4. Trends in Turnaround Times, 2010–2015.
*In 2014, the DST benchmark was changed to reflect the new recommendation of DST results within 17 days of ID of MTBC.













































State PHL with no or limited
courier service (n = 23)
State PHL with state-
wide courier (n = 27)
City or County PHL (n = 6)
Received in PHL from date of collection
State PHL that had availability of a statewide courier service achieved TAT for specimen delivery at higher levels 
than did those with no or limited courier service. While city and county PHL achieved this benchmark at higher 
levels, rapid specimen delivery remains challenging for state laboratories: many of which are located in large 
geographical areas and depend on a patchwork of delivery services, including U.S. Postal Service, commercial 
couriers, and other transportation methods. Please see Technical Note #3 for explanation of how courier 
availability was determined.
Figure 5. Specimen Receipt TAT Comparisons by Courier Availability, 2015. 
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Comparison of PHL Testing to Surveillance Reports
Table 3. Comparison of National TB Surveillance Data and PHL Self-Reported Data, 2012–2015.
Year
2012 2013 2014 2015
National TB  
Surveillance 
data
Total no. TB cases 9,945 9,565 9,421 9,557
No. culture-confirmed  
TB cases 7,598 7,358 7,226 7,410
No. culture-confirmed TB 
cases with DST reported 7,250 7,108 6,949 7,209
Self-reported  
PHL data  
(n=58 PHL  
reporting)
No. NAAT positive 
MTBC patients (% of 
culture-confirmed TB 












(% of culture-confirmed 










No. patient DST 
performed (% of 
culture-confirmed TB 










In Table 3, self-reported Cooperative Agreement data are compared to National TB surveillance data5 for 
2012–2015. In this analysis, PHL appeared to have identified approximately half of the reported culture 
confirmed TB cases and detected 36–44% of MTBC by direct detection (NAAT). PHL also appeared to have 
performed a greater percentage of more complex testing such as DST for culture confirmed cases. Because 
these data are drawn from different sources and may not reflect redundant testing, this comparison represents 
an estimation of the contribution of PHL services to overall TB testing in the United States
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Methods in Public Health Laboratories
Figure 6. NAAT Methods, 2016.
Figure 7. Primary ID Methods, 2016.
Methods used by PHL supported, in part, by the TB Cooperative Agreement for NAAT, ID, DST, and IGRA, are 
displayed in Figures 6–9. For each figure, total number of PHL equals 58. As new technology emerges and 
laboratories adjust testing algorithms, methods used will continue to evolve. Please see Technical Note #4 for 












Sequencing, 2 Xpert MTB/RIF, 1 PRA, 1
Xpert™ MTB/RIF, real-time PCR, and MTD™ assays make up 86% of NAAT methods used. 
Although many PHL utilize more than one method within their ID algorithm, the primary 
method described from report narratives is included for each laboratory. 
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Bactec MGIT, 41
Referred - DST 
Reference Center, 10
Referred - Other, 5
Indirect AP, 1 Trek Sensititre, 1
None, 32
Quantiferon in other 
section of PHL, 14
Quantiferon in 
Mycobacteriology 
section of PHL, 10
T-Spot, 2
Figure 8. First-line DST Methods, 2016.
Figure 9. IGRA Methods, 2016.
The majority of PHL continue to perform first-line DST via the Bactec MGIT™ system. 
Over the past year, 10 laboratories performing less than 50 DST per year have utilized 
the APHL/CDC National TB DST Reference Center for susceptibility testing. 
As use of IGRA expands throughout public health laboratories, 24 laboratories performed 
Quantiferon®, with 10 of these performing testing within the Mycobacteriology section 
and 14 testing within another section of the PHL. Two laboratories utilized T-Spot® by 
referring specimens to a national testing center. The majority of PHL, however, are not 
currently performing IGRA testing. 
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